↓ Skip to main content

Open-label placebo treatment in chronic low back pain: a randomized controlled trial

Overview of attention for article published in Pain (03043959), December 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 6,056)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
180 news outlets
blogs
18 blogs
twitter
1099 tweeters
facebook
21 Facebook pages
wikipedia
2 Wikipedia pages
googleplus
3 Google+ users

Citations

dimensions_citation
252 Dimensions

Readers on

mendeley
319 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Open-label placebo treatment in chronic low back pain: a randomized controlled trial
Published in
Pain (03043959), December 2016
DOI 10.1097/j.pain.0000000000000700
Pubmed ID
Authors

Cláudia Carvalho, Joaquim Machado Caetano, Lidia Cunha, Paula Rebouta, Ted J. Kaptchuk, Irving Kirsch

Abstract

This randomized controlled trial was performed to investigate whether placebo effects in chronic low back pain could be harnessed ethically by adding open-label placebo (OLP) treatment to treatment as usual (TAU) for 3 weeks. Pain severity was assessed on three 0- to 10-point Numeric Rating Scales, scoring maximum pain, minimum pain, and usual pain, and a composite, primary outcome, total pain score. Our other primary outcome was back-related dysfunction, assessed on the Roland-Morris Disability Questionnaire. In an exploratory follow-up, participants on TAU received placebo pills for 3 additional weeks. We randomized 97 adults reporting persistent low back pain for more than 3 months' duration and diagnosed by a board-certified pain specialist. Eighty-three adults completed the trial. Compared to TAU, OLP elicited greater pain reduction on each of the three 0- to 10-point Numeric Rating Scales and on the 0- to 10-point composite pain scale (P < 0.001), with moderate to large effect sizes. Pain reduction on the composite Numeric Rating Scales was 1.5 (95% confidence interval: 1.0-2.0) in the OLP group and 0.2 (-0.3 to 0.8) in the TAU group. Open-label placebo treatment also reduced disability compared to TAU (P < 0.001), with a large effect size. Improvement in disability scores was 2.9 (1.7-4.0) in the OLP group and 0.0 (-1.1 to 1.2) in the TAU group. After being switched to OLP, the TAU group showed significant reductions in both pain (1.5, 0.8-2.3) and disability (3.4, 2.2-4.5). Our findings suggest that OLP pills presented in a positive context may be helpful in chronic low back pain.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Twitter Demographics

The data shown below were collected from the profiles of 1,099 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 319 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Japan 1 <1%
Germany 1 <1%
South Africa 1 <1%
Unknown 315 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 57 18%
Student > Master 44 14%
Researcher 30 9%
Student > Ph. D. Student 28 9%
Other 24 8%
Other 73 23%
Unknown 63 20%
Readers by discipline Count As %
Medicine and Dentistry 78 24%
Psychology 57 18%
Nursing and Health Professions 32 10%
Neuroscience 20 6%
Sports and Recreations 11 3%
Other 41 13%
Unknown 80 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 1997. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2022.
All research outputs
#3,672
of 22,132,418 outputs
Outputs from Pain (03043959)
#1
of 6,056 outputs
Outputs of similar age
#34
of 294,802 outputs
Outputs of similar age from Pain (03043959)
#1
of 76 outputs
Altmetric has tracked 22,132,418 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,056 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,802 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.